By ICR | Podcast
Testing the population is a vital step in the pursuit of disease control. During the COVID-19 pandemic, when the biotech industry was challenged to rapidly adapt and produce safe, effective testing at an almost unimaginable scale, businesses were forced to adapt and re-think the way diagnostic tests are designed, distributed, and safely conducted in order to keep up with demand.
Our guest today is Jeff Fischer. Jeff is the co-founder and president of Longhorn Vaccines & Diagnostics LLC, an industry leading biotechnology company that has been on the frontlines of the battle with COVID-19. From 2007 to 2017, Jeff served as CFO of Longhorn. Jeff has previous experience in the biotech industry as an executive VP and CFO, and he is also a former infantry officer in the United States Marine Corps.
In this episode, Jeff explains Longhorn’s innovative FDA-approved PrimeStore Molecular Transport Medium – a product that has changed the way viruses are tested, how seeking FDA approval helped with mass rollout in a time of crisis, and how Longhorn found an unusual solution to a shortage of essential supplies.
Highlights:
Links:
Feedback:
If you have questions about the show or have a topic in mind you’d like discussed in future episodes, email our producer, elizabeth@lowerstreet.co.
;)